Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/143114
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | MAP17 (PDZKIP1) expression determines sensitivity to the proteasomal inhibitor bortezomib by preventing cytoprotective autophagy and NFκB activation in breast Cancer |
Autor: | Muñoz-Galván, Sandra CSIC ORCID ; Gutiérrez, Gabriel; Pérez, Marco CSIC ORCID; Carnero, Amancio CSIC ORCID | Fecha de publicación: | jun-2015 | Editor: | American Association for Cancer Research | Citación: | Molecular Cancer Therapeutics 14(6): 1454-1465 (2015) | Resumen: | © 2015 American Association for Cancer Research. MAP17 is a small nonglycosylated membrane protein that is overexpressed in a high percentage of carcinomas. High levels of MAP17 enhance the tumorigenic properties of tumor cells by increasing oxidative stress, which is dependent on Na+-coupled cotransport. Here, we show that MAP17 is associated with proteins involved in protein degradation and that proteasome inhibition induces autophagy. To analyze whether MAP17 could also alter this process, we used the proteasome inhibitor bortezomib (Velcade, PS-341), which is approved for the treatment of multiple myeloma and mantle cell lymphoma, although it has a high rate of resistance emergence and poor efficacy in solid tumors. We provide evidence that bortezomib induces a cytoprotective effect by activating autophagy and NFkB nuclear translocation, responses that are repressed in the presence of high levels of MAP17 both in vitro and in vivo. Indeed, patients with multiple myeloma treated with bortezomib showed higher response rates and a longer time to progression associated with increased levels of MAP17 expression. The MAP17-induced sensitivity to bortezomib is dependent on the oxidative status of the cells and the activity of Na+-coupled transporters because treatment with antioxidants or the inhibitor furosemide restores the cytoprotective activity induced by bortezomib. Therefore, bortezomib induces a prosurvival response through cytoprotective autophagy and NFκB nuclear translocation, which is repressed by high levels of MAP17. Wepropose that the levels of MAP17could be used as a prognostic marker to predict the response to bortezomib in hematologic malignancies and in other tissues that are not commonly responsive to the drug. | Versión del editor: | http://doi.org/10.1158/1535-7163.MCT-14-1053 | URI: | http://hdl.handle.net/10261/143114 | DOI: | 10.1158/1535-7163.MCT-14-1053 | Identificadores: | e-issn: 1538-8514 issn: 1535-7163 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
26
checked on 13-abr-2024
WEB OF SCIENCETM
Citations
24
checked on 26-feb-2024
Page view(s)
191
checked on 22-abr-2024
Download(s)
67
checked on 22-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.